

THE REMARKS

The Amendment

Claims 1-4, 6 and 8-16 were pending prior to entering the amendments.

Claim 8 is amended to clarify the meaning of the claim.

Claim 16 is amended to insert "methyl." Support for the amendment can be found in the title of Example 8.

No new matter is added in the amendments. The Examiner is requested to enter the amendment.

The Response

35 U.S.C. §112, First Paragraph, Rejection

Claims 1 and 3-4 are rejected under 35 U.S.C. §112, first paragraph, allegedly because the specification, while being enabling for treating schizophrenia, does not reasonably provide enablement for treating autism, Alzheimer's disease or the entire genus of CNS disease which is accompanied with cognitive disorders or mnestic disorders.


Applicants do not agree with the rejection. However, to further the allowance of the application, Applicants have amended Claim 1 to recite a method for treating schizophrenia. Claims 2-4 are cancelled.

CONCLUSION

For all the foregoing reasons, reconsideration of and withdrawal of all outstanding rejections is respectfully requested. The Examiner is earnestly solicited to allow all claims, and pass this application to issuance.

Date: June 10, 2008

Respectfully submitted,



Viola T. Kung, Ph.D. (Reg. No. 41,131)

HOWREY LLP
2941 Fairview Park Drive, Box 7
Falls Church, VA 22042
Tel: (650) 798-3570